Daiichi Sankyo to close UK R&D unit

11 February 2016

Japanese drug major Daiichi Sankyo (TYO: 4568) says it has decided to close its development subsidiary, Daiichi Sankyo Development (DSD: based in Gerrards Cross, England).

This decision is part of the company’s effort to streamline and enhance the efficiency of its research and development operations that we previously announced on December 1, 2015. in the release entitled, “Daiichi Sankyo Announces Reorganization of its Research & Development Structure.”

DSD presently employs around 80 people engaged in the development of pharmaceuticals in Europe. Upon its closure, Daiichi Sankyo will transfer essential development capabilities to its American development subsidiary, Daiichi Sankyo Pharma Development (based in Edison, New Jersey), and to its European subsidiary, Daiichi Sankyo Europe GmbH (based in Munich, Germany).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK